Patients and advocates can play a crucial role by: - Participating in clinical trials. - Engaging with patient advocacy groups. - Providing feedback to regulatory agencies. Their involvement can help ensure that the orphan designation program remains patient-centered and effective in addressing the needs of those with rare cancers.
